CURX
Curanex Pharmaceuticals IncCompany Information
- Company Name
- Curanex Pharmaceuticals Inc
- CIK
- CIK0002025942
- Category
- <br>Emerging growth company
- Ticker: Exchange
- CURX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CURX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 282,926
- Shares outstanding
- 28,364,812
- Ownership
- 1.00%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 16.36%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||
| Cash | 3 | 4 | 5 | 6 | 0 | ||||||
| Prepaid Expense Current | 2 | 4 | 6 | 9 | 0 | ||||||
| Other Assets Current | - | - | - | - | 1 | ||||||
| Assets Current | 5 | 8 | 11 | 14 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 5 | 8 | 12 | 14 | 1 | ||||||
Liabilities Current | |||||||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | ||||||
| Interest Payable Current | - | - | - | - | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | - | 0 | ||||||
| Liabilities | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | |||||||||||
| Long Term Loans Payable | - | - | - | - | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 16 | 16 | 16 | 16 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -11 | -8 | -5 | -2 | -1 | ||||||
| Stockholders Equity | 5 | 8 | 11 | 14 | 0 | ||||||
| Liabilities And Stockholders Equity | 5 | 8 | 12 | 14 | 1 | ||||||
| Common Stock Shares Authorized | 475 | 475 | 475 | 475 | 475 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 28 | 28 | 28 | 28 | 24 | ||||||
| Shares Outstanding | 28 | 28 | 28 | 28 | 24 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Outstanding | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCuranex Pharmaceuticals Inc (CURX) — SEC Financial Statements & Analysis
Curanex Pharmaceuticals Inc (CURX) is a pharmaceutical preparations company, incorporated in NV. Curanex Pharmaceuticals Inc trades on Nasdaq as: CURX. Curanex Pharmaceuticals Inc (CURX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Curanex Pharmaceuticals Inc carries a market cap of $150.33M, a P/E ratio of -14.17x, a P/B ratio of 31.40x, an enterprise value of $147.40M, and an EV/EBITDA multiple of -13.79x. On profitability, it posts a Return on Equity (ROE) of -416.48%, a Return on Assets (ROA) of -361.91%, and a Return on Invested Capital (ROIC) of -1045.11%. Per share, it reports EPS of $-0.37, diluted EPS of $-0.37, free cash flow per share of $-0.43, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 45.95x, a quick ratio of 28.17x, working capital of $4.69M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, an interest coverage ratio of -1962.97x, free cash flow of $-12.08M (TTM), and net debt of $-2.94M. Figures sourced from SEC EDGAR.
- Market Cap
- $150.33M
- P/E TTM
- -14.17x
- EPS TTM
- $-0.37
- P/B TTM
- 31.40x
- ROE TTM
- -416.48%
- ROA TTM
- -361.91%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-12.08M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Curanex Pharmaceuticals Inc in?
Curanex Pharmaceuticals Inc (CURX) operates in the Pharmaceutical Preparations industry.
What exchange does CURX trade on?
Curanex Pharmaceuticals Inc (CURX) trades on the Nasdaq.
Where is Curanex Pharmaceuticals Inc incorporated?
Curanex Pharmaceuticals Inc is incorporated in NV.
When was Curanex Pharmaceuticals Inc (CURX)'s most recent SEC filing?
Curanex Pharmaceuticals Inc (CURX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is CURX's market cap?
Curanex Pharmaceuticals Inc (CURX) has a market capitalization of $150.33M as of 2026-06-30.
What is CURX's EPS (earnings per share)?
Curanex Pharmaceuticals Inc (CURX)'s trailing twelve month EPS is $-0.37 as of 2026-06-30.
What is CURX's ROE (return on equity)?
Curanex Pharmaceuticals Inc (CURX)'s trailing twelve month Return on Equity (ROE) is -416.48% as of 2026-06-30.
What is CURX's ROA (return on assets)?
Curanex Pharmaceuticals Inc (CURX)'s trailing twelve month Return on Assets (ROA) is -361.91% as of 2026-06-30.
What is CURX's ROIC (return on invested capital)?
Curanex Pharmaceuticals Inc (CURX)'s trailing twelve month Return on Invested Capital (ROIC) is -1045.11% as of 2026-06-30.
What is CURX's EV/EBITDA?
Curanex Pharmaceuticals Inc (CURX)'s trailing twelve month EV/EBITDA is -13.79x as of 2026-06-30.